Sample size and power training for use in clinical trials

Webinar

Improving Sample Size
Using Bayesian Thinking

Hybrid Bayesian/Frequentist Methods for Sample Size Determination

 

This webinar has now ended
Watch on Demand

About the webinar

In this webinar, we will explore some of the issues faced when statistical power is used as the sole metric for trial success when conducting a sample size determination.

We will show how Bayesian assurance can be used as a complementary metric, that allows parameter uncertainty to be formally incorporated into the trial design.

We also discuss some of the limitations of using a traditional confidence interval as the measure for success and examine Mixed Bayesian/Likelihood HPD interval and consensus-based approaches to interval construction as potential alternatives.

Learn how to overcome the challenges associated with:

  • Underpowered or overpowered trials
    (due to inaccurate initial parameter estimates)
  • Using a confidence interval to measure trial success
  • Using expert opinions to construct a prior for Bayesian Methods

Duration - 60 minutes

Speaker: Paul Murphy, Research Statistician, nQuery

More about the webinar

Sample size determination is an essential procedure when designing any phase II or phase III clinical trial. The sample size is often chosen as the minimum number that achieves a target power, where this target is often 80% or 90%.

However, the actual power is often conditional on many estimates such as the treatment effect size or nuisance parameters such as the standard deviation. A sensitivity analysis can be used to explore the effect of varying these parameters, but this ad-hoc approach has limitations.

Bayesian assurance (sometimes called Bayesian power) allows the trialist to formally address parameter uncertainty by assigning a prior distribution to one or more of the parameter estimates. Through this approach, we calculate the unconditional probability of trial success and thus, Bayesian assurance is often considered to be a more accurate representation of the “true probability of success”.

Confidence interval lengths are another common metric for success when designing a trial. However, these frequentist intervals are often misinterpreted and misunderstood. Bayesian credible intervals offer a more intuitive interpretation in addition to the ability to incorporate prior knowledge into the design.

Mixed Bayesian/Frequentist HPD intervals are a hybrid approach that exhibits both credible and confidence interval quantities. This is achieved through the use of an uninformative prior and is an attractive option for those who require a confidence interval in their final analysis but would like to take advantage of Bayesian properties.

For many, the requirement to specify a prior distribution is a barrier to using any Bayesian approach. This is particularly true when previous data is not available and expert opinions must be used instead.

The Sheffield Elicitation Framework (SHELF) is outlined as a protocol to help structure and formalise this elicitation process.

Finally, we look at a consensus-based approach to interval construction which allows the trialist to incorporate two differing expert opinions into the trial design.

Watch Now

All info submitted is secure. View our privacy policy.


About Our Host
Paul Murphy

Paul-Murphy-nQuery-Researcher

 


Research Statistician, nQuery

Reducing the risk & cost of clinical trials, for innovative organizations such as:
Sanofi-updated-grey
worldwide-clinical-trials
Covance-G_Logo
quintiles_logo_2017_grey
FDA_G_Logo
AstellasG_Logo
celgene_logo_download
Boehringer_Ingelheim_Logo-png-updated
PRA_Health_Sciences
Astrazeneca logo
Amgen_G_Logo
Novartis_G_Logo
abbvie-logo-updated_tmp15240
Merck_GLogo
Biogen-updated-logo
Ipsen-logo-only
Eli_Lilly_and_Company-G_Logo
Is there someone in your network that would be interested in our webinar?
Share this page by clicking below.